B Cell Malignancies clinical trials

Explore recruiting b cell malignancies clinical trials.

Recruiting b cell malignancies studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

B Cell Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)

Spain, Germany, Denmark, Italy, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

Italy, Germany, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Study of BGB-11417 in Patients with Mature B Cell Malignancies

Italy, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Study of PIT565 in relapsed and/or refractory B-cell malignancies

Spain, Belgium, France, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Phase Ia/Ib Study of UBX-303061 in Subjects with Relapsed/Refractory B-Cell Malignancies

Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

Spain, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

B Cell Malignancies trials by city

B Cell Malignancies in Toronto B Cell Malignancies in Vancouver B Cell Malignancies in Montreal B Cell Malignancies in Calgary B Cell Malignancies in Edmonton B Cell Malignancies in Ottawa B Cell Malignancies in Winnipeg B Cell Malignancies in Quebec City B Cell Malignancies in Hamilton B Cell Malignancies in Kitchener B Cell Malignancies in London B Cell Malignancies in Halifax B Cell Malignancies in New York B Cell Malignancies in Los Angeles B Cell Malignancies in Chicago B Cell Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease